Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

NCT06966401 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT06966401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06966401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
Lead sponsor
Neurocrine Biosciences
Phase
Phase 3
Overall status
Recruiting
Start date
April 16, 2025
Completion date
May 31, 2030
Enrollment
850 (estimated)
Sites
106

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder